| Combination Therapy for BRAF-V600E Metastatic CRCm (NCT06411600) | Vall d'Hebron Institute of Oncology | 2024-05-17 |
| Interferon-gamma as Adjunctive Therapy in Chronic Pulmonary Aspergillosis: a Randomised Feasibility Study (NCT05653193) | Manchester University NHS Foundation Trust | 2024-05-17 |
| A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (NCT06393712) | Alnylam Pharmaceuticals | 2024-05-17 |
| A Prospective, Single-arm, Phase II Clinical Trial to Evaluate the Efficacy and Safety of Tafolecimab and Sintilimab Combined With Chemotherapy in Patients With Advanced or Metastatic Driver Gene-negative Non-small Cell Lung Cancer After Failure of First-line Immunotherapy. (NCT06421298) | Jinghui Wang | 2024-05-17 |
| Zanubrutinib Plus Rituximab for Patients With Indolent Mantle Cell Lymphoma (NCT05635162) | University College, London | 2024-05-17 |
| Low-dose Buprenorphine as a Modulator of Social Motivation in Schizophrenia (NCT05778591) | University of California, Los Angeles | 2024-05-17 |
| Efficacy and Safety of HRS-7535 Tablets in T2DM Subjects Poorly Controlled With Metformin and SGLT2i. (NCT06393348) | Shandong Suncadia Medicine Co., Ltd. | 2024-05-17 |
| Antibiotic Tumescent For Chronic Wounds (NCT06327113) | University of California, Los Angeles | 2024-05-17 |
| Combining EPI-7386 With Enzalutamide and Androgen Deprivation Therapy for Metastatic Hormone-Sensitive Prostate Cancer (NCT06312670) | Pedro Barata, MD, MSc | 2024-05-16 |
| Phase 1b/2 Study of LDRT in Combination With AK104 Plus Chemotherapy as First-line Treatment for ES-SCLC (NCT06477523) | Sichuan University | 2024-05-16 |
| RC48 Treatment for Platinum Sensitive Recurrent Ovarian Cancer With HER2 Expression (NCT06420973) | Peking University Cancer Hospital & Institute | 2024-05-16 |
| Fluorouracil Treatment Via Colon for Colorectal Cancer (NCT06385418) | The Second Hospital of Nanjing Medical University | 2024-05-16 |
| Fractionated Stereotactic Radiotherapy Plus Second-generation Antiandrogen for Oligometastatic Castration-resistant Prostate Cancer Patients. (NCT07717268) | Instituto de Investigación en Oncología Radioterápica - Fundación Española de Oncología Radioterápic | 2024-05-16 |
| Safety and Efficacy of 3 Dose Levels of NMD670 in Adult Patients With Myasthenia Gravis (NCT06414954) | NMD Pharma A/S | 2024-05-16 |
| SHR-A1811 in Combination With Adebrelimab for the Treatment of HER2 Low-expressing Metastatic Breast Cancer (NCT06411457) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2024-05-16 |
| COVID-19 Rapid Test-to-Treat With African American Churches (Faithful Response II) (NCT07450209) | University of Missouri, Kansas City | 2024-05-15 |
| Thoracic Radiotherapy for Patients With Metastatic (Stage IV) Non-Small Cell Lung Cancer at High Risk of Symptomatic Progression Within the Thorax (NCT06262321) | University of Rochester | 2024-05-15 |
| Erector Spinae Plane Block vs Local Infiltration Following Fusion Surgery (NCT06199999) | Rashmi Mueller | 2024-05-15 |
| Evaluating Emetine for Viral Outbreaks (EVOLVE) (NCT05889793) | Johns Hopkins University | 2024-05-15 |
| Mindfulness Engaged Neurostimulation for Depression (NCT06399406) | University of California, San Diego | 2024-05-15 |
| Infusion of Allogeneic Stromal Mesenchymal Stem Cells From Wharton´s Jelly in Patients With Diffuse Cutaneous Systemic Sclerosis With Refractory Pulmonary Involvement to Treatment (NCT07542067) | Fundación Neumologica Colombiana | 2024-05-15 |
| Cadonilimab in Combination With Lenvatinib and Hepatic Arterial Infusion Chemotherapy (HAIC) for the Treatment of Unresectable Hepatocellular Carcinoma (NCT06406634) | Hunan Cancer Hospital | 2024-05-15 |
| CHOP Plus Mosunetuzumab as First Line in Patients With Richter´s Syndrome: a Phase II Study of the Spanish Group of CLL (NCT06926205) | GELLC (Grupo Español de Leucemia Linfocítica Crónica) | 2024-05-15 |
| Safety and Efficacy of KLS-1 Monotherapy in Malignant Neoplasms (NCT06506643) | Vector Vitale LLC | 2024-05-15 |
| Study to Evaluate a New Method to Detect Residual Tumours During Surgery for Prostate Cancer Using Confocal Microscopy (NCT06398470) | University College, London | 2024-05-15 |
| A Study of JMT203 in Patients With Cancer Cachexia (NCT06868849) | Shanghai JMT-Bio Inc. | 2024-05-15 |
| Explore the Efficacy and Mechanism of Action of Tezepelumab in Eosinophilic Granulomatosis With Polyangiitis (NCT06230354) | Imperial College London | 2024-05-15 |
| A Phase Ib/II Study of BY101298 , an Oral DNA-PK Inhibitor, Combined with Radiotherapy in Patients with Malignant Solid Tumors (NCT06524804) | Chengdu Baiyu Pharmaceutical Co., Ltd. | 2024-05-15 |
| A Study to Evaluate TOUR006 in Patients With Chronic Kidney Disease and Elevated Hs-CRP (NCT06362759) | Tourmaline Bio, Inc., a Novartis Company | 2024-05-15 |
| Reduced Dose Radiotherapy for the Treatment of Indolent Non-Hodgkin Lymphoma (NCT06386315) | Mayo Clinic | 2024-05-15 |
| Vitamin A and D Supplementation in Allogeneic HCT (NCT06508099) | St. Petersburg State Pavlov Medical University | 2024-05-15 |
| Nimotuzumab Plus NALIRIFOX in Locally Advanced Pancreatic Cancer (NCT06429904) | Peking Union Medical College Hospital | 2024-05-15 |
| Autoimmune Disease Treatment With Mesenchymal Stem Cells (MSCs) and CAR-T Cells (NCT06435897) | Shenzhen Geno-Immune Medical Institute | 2024-05-15 |
| Clinical Trail of Neoadjuvant of Tislelizumab Combined With Palbociclib in Patients With Platinum-refractory Bladder Urothelial Carcinoma (NCT06364956) | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 2024-05-15 |
| Cadonilimab in Combination With Anlotinib in the Treatment of Locally Progressive or Metastatic Melanoma With First-Line Therapy Failure (NCT06327698) | Hunan Cancer Hospital | 2024-05-15 |
| A Phase II Study of SSGJ-707 Monotherapy in First-line PD-L1 Positive Advanced NSCLC Patients (NCT06361927) | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | 2024-05-15 |
| Chidamide Combined With Sintilimab and Bevacizumab for the First-line Treatment of Advanced Liver Cancer (NCT06408623) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2024-05-15 |
| A Phase 1/2 Study to Evaluate CHM-2101, an Autologous Cadherin 17 Chimeric Antigen Receptor (CAR) T Cell Therapy (NCT06055439) | Chimeric Therapeutics | 2024-05-15 |
| ICP-248 in Combination With Orelabrutinib in Treatment-naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (APEX-03) (NCT06378138) | Beijing InnoCare Pharma Tech Co., Ltd. | 2024-05-15 |
| A Study to Test Whether BI 764524 Helps People With an Eye Condition Called Diabetic Retinopathy (NCT06321302) | Boehringer Ingelheim | 2024-05-15 |
| MRD-Directed Consolidation With Epcor-only or Epcor-R2 Post Anti-CD19 CAR TCell Therapy for Large B-Cell Lymphoma (NCT06414148) | Peter MacCallum Cancer Centre, Australia | 2024-05-14 |
| A Clinical Study to Evaluate the Safety and Efficacy of ETX101 in Infants and Children With SCN1A-Positive Dravet Syndrome (NCT05419492) | Encoded Therapeutics | 2024-05-14 |
| MID-STEP (MIDodrine for Sepsis Treatment and Early vasoPressor Weaning) Trial (NCT06319248) | Mayo Clinic | 2024-05-14 |
| Iscador® P (Mistletoe) Immunotherapy for Recurrent Resectable Osteogenic Sarcoma (NCT05726383) | Hackensack Meridian Health | 2024-05-14 |
| Phase I/II Open-label Study Evaluating The Safety And Efficacy of Concomitant Administration of Anti-CD19 CAR T-cell Therapy and Lenalidomide in Refractory/Relapsed Chronic Lymphocytic Leukemia Patients. (NCT06762431) | Vitebsk Regional Clinical Cancer Centre | 2024-05-14 |
| Trial to Assess the Safety and Preliminary Efficacy of GEN1055 on Malignant Solid Tumors as Monotherapy and as Combination Therapy (NCT06391775) | Genmab | 2024-05-14 |
| Use of Elranatamab in Patients With High-risk Smoldering Multiple Myeloma (NCT06183489) | Stichting European Myeloma Network | 2024-05-14 |
| INBRX-106 in Combination With Pembrolizumab in First-line PD-L1 CPS≥20 HNSCC (NCT06295731) | Inhibrx Biosciences, Inc | 2024-05-14 |
| Pembrolizumab, Lenvatinib and IL-15 Superagonist N-803 in Combination With HER2 Targeting Autologous Dendritic Cell (AdHER2DC) Vaccine in Participants With Advanced or Metastatic Endometrial Cancer (NCT06253494) | National Cancer Institute (NCI) | 2024-05-14 |
| A Clinical Trial of TQ05105 Tablets Combined With TQB3909 Tablets in the Treatment of Myelofibrosis (MF) (NCT06245941) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2024-05-13 |
| A Trial of SHR-A2102 With or Without Antitumor Therapy in Advanced Solid Tumors (NCT06417554) | Shanghai Hengrui Pharmaceutical Co., Ltd. | 2024-05-13 |
| Peptide Vaccine To Prevent Acquired Resistance In Patients With Advanced ALK+ NSCLC (NCT05950139) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2024-05-13 |
| Long Term Follow-up Study of Type-1 Gaucher Subjects Post FLT201 Dose (GALILEO-2) (NCT06545136) | Spur Therapeutics | 2024-05-13 |
| A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies (NCT06395519) | 858 Therapeutics, Inc. | 2024-05-13 |
| To Evaluate the Effects of NMRA-335140 on Symptoms of Major Depression in Participants With Bipolar II Disorder. (NCT06429722) | Neumora Therapeutics, Inc. | 2024-05-13 |
| A Study of FDA022-BB05 in Advanced/Metastatic Solid Tumors (NCT06413615) | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. | 2024-05-13 |
| Pramipexole to Enhance Social Connections (NCT06269146) | University of California, San Diego | 2024-05-13 |
| Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy (NCT06309966) | Biohaven Therapeutics Ltd. | 2024-05-13 |
| Efficacy and Safety of Avatrombopag in the Treatment of Thrombocytopenia After Haplo-HSCT (NCT06202625) | Peking University People's Hospital | 2024-05-13 |
| Central-boost Ablative Radiation Therapy for Solid Tumors (CBART) (NCT06427460) | Changhai Hospital | 2024-05-12 |
| Ketogenic Diet Improves Thrombocytopenia in Cancer Patients (NCT06106139) | Baoling Guo | 2024-05-12 |
| Inosine Reverse Chemo Resistance in Triple Negative Breast Cancer (NCT06355024) | Fudan University | 2024-05-11 |
| Frontline Combination CAR-T Cell Therapy for Multiple Myeloma or Plasmacytoma (NCT06429150) | Shenzhen Geno-Immune Medical Institute | 2024-05-11 |
| An Open-label Study of a Gene Therapy Product (Vebeglogene Autotemcel) in Transfusion Dependent Beta-Thalassemia (NCT06308159) | Lantu Biopharma | 2024-05-11 |
| To Evaluate the Efficacy of Oral Molecular Hydrogen Supplement in Patients With Chronic Diseases (NCT06401785) | HoHo Biotech | 2024-05-11 |
| Evaluation of Safety and Efficacy of Gene Therapy Drug in the Treatment of Spinal Muscular Atrophy (SMA) Type 3 Patients (NCT06421831) | GeneCradle Inc | 2024-05-10 |
| A Study of ZG005 Combined With Donafenib in Patients With Advanced Solid Tumor (NCT06239298) | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | 2024-05-10 |
| A Study of a N, N-dimethyltryptamine (DMT) Analog (CYB004) in Participants With Generalized Anxiety Disorder (GAD) (NCT06051721) | Cybin IRL Limited | 2024-05-10 |
| Camrelizumab Plus Fluzoparib for TP-53 Mutated Endometrial Cancer (NCT06413992) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2024-05-10 |
| Oxidative Phosphorylation Targeting In Malignant Glioma Using Metformin Plus Radiotherapy Temozolomide (NCT04945148) | Hopital Foch | 2024-05-10 |
| A Single Arm, Single Centered Phase II Trial on the Combination of Adebrelimab, Surufatinib and Irinotecan Liposome-based HAIC in Advanced iCC (NCT06375642) | Tianjin Medical University Cancer Institute and Hospital | 2024-05-10 |
| Combination Therapy in Patients With Localized Pancreatic Ductal Adenocarcinoma (NCT06048484) | Gulam Manji | 2024-05-10 |
| Investigating Near-Threshold Perception During Anesthetic Sedation (NCT06403852) | University of Michigan | 2024-05-10 |
| Hyperthermia Enhanced Re-irradiation of Loco-regional Recurrent Tumors (NCT04889742) | Charite University, Berlin, Germany | 2024-05-10 |
| Probiotics Combined with Enteral Nutrition Reduces Postoperative Infectious Complications in PD (NCT06719596) | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | 2024-05-10 |
| Antitumor Activity of Neoadjuvant Chemotherapy with or Without HCW9218 in Metastatic Advanced Stage Ovarian Cancer (NCT05145569) | Haider Mahdi | 2024-05-10 |
| A Phase 2 Study to Investigate Efficacy and Safety of HZN-1116 in Participants With Sjogren's Syndrome (NCT06312020) | Amgen | 2024-05-09 |
| Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors (NCT06425926) | Georgiamune Inc | 2024-05-09 |
| A Clinical Study to Evaluate the Safety and Efficacy of ETX101, an AAV9-Delivered Gene Therapy in Children With SCN1A-positive Dravet Syndrome (NCT06283212) | Encoded Therapeutics | 2024-05-09 |
| Quaratusugene Ozeplasmid (Reqorsa) and Atezolizumab Maintenance Therapy in ES-SCLC Patients (NCT05703971) | Genprex, Inc. | 2024-05-09 |
| Comparing Efficacy and Safety of CTO0303 in Pediatric Subjects (NCT06609525) | Taejoon Pharmaceutical Co., Ltd. | 2024-05-09 |
| Short Course Radiotherapy With Sequential Disitamab Vedotin Combined With S-1 and Sintilimab as Whole Course Neoadjuvant Therapy for HER2 Expressed Locally Progressive Gastric Cancer (NCT06487429) | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 2024-05-08 |
| A Study to Test Long-term Treatment With Spesolimab in People With a Skin Condition Disease Called Hidradenitis Suppurativa (HS) Who Took Part in a Previous Study With Spesolimab (NCT06241573) | Boehringer Ingelheim | 2024-05-08 |
| Dydrogesterone Versus GnRH Antagonist in Poor Responders Undergoing Double Ovarian Stimulation (NCT06212102) | Bedaya Hospital | 2024-05-08 |
| A Clinical Study of Purinostat Mesylate for Injection in Patients With Advanced Solid Tumors (NCT06431243) | Chengdu Zenitar Biomedical Technology Co., Ltd | 2024-05-08 |
| Short-course Radiotherapy Combined With CapeOx and PD-1 Inhibitor After Local Excision for High-risk Early Rectal Cancer (TORCH-LE) (NCT06455124) | Fudan University | 2024-05-08 |
| RECOVER-AUTONOMIC: Platform Protocol, Appendix A (IVIG) (NCT06305793) | Kanecia Obie Zimmerman | 2024-05-08 |
| A Study of CDX-1140, a CD40 Agonist, in Combination With Capecitabine and Oxaliplatin (CAPOX) and Keytruda in Subjects With Biliary Tract Carcinoma (BTC) (NCT05849480) | National Cancer Institute (NCI) | 2024-05-08 |
| A Multicenter Open Clinical Study of Safety, Tolerability, Pharmacokinetic Profile, and Initial Clinical Efficacy of BAT 8010 for Injection Combined With BAT 1006 in the Treatment of Locally Advanced or Metastatic Tumors (NCT06376136) | Bio-Thera Solutions | 2024-05-08 |
| A Phase II/III Trial to Evaluate the Efficacy and Safety of Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine in Metastatic Pancreatic Cancer (NCT06361888) | Hutchmed | 2024-05-08 |
| A Phase 2 Trial of Foscenvivint in Liver Cirrhosis Patients Caused by HIV/HCV Co-infection With Hemophilia (OP-724-H201) (NCT06144086) | Kiminori Kimura, MD | 2024-05-08 |
| Neoadjuvant Chemotherapy Plus Camrelizumab for FIGO Stage IB1 Cervical Cancer (NCT06289062) | Tongji Hospital | 2024-05-08 |
| Testing the Use of Neratinib or the Combination of Neratinib and Palbociclib Targeted Treatment for HER2+ Solid Tumors (A ComboMATCH Treatment Trial) (NCT06126276) | National Cancer Institute (NCI) | 2024-05-07 |
| QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Early High-Risk TNBC Breast Cancer (NCT06404736) | Fudan University | 2024-05-07 |
| Acute Effects of Paraxanthine on Energy and Focus (NCT06628596) | Iovate Health Sciences International Inc | 2024-05-07 |
| A Study of Dostarlimab in Combination With Carboplatin-paclitaxel in Japanese Participants With Primary Advanced or Recurrent Endometrial Cancer (NCT06317311) | GlaxoSmithKline | 2024-05-07 |
| A Study of Axicabtagene Ciloleucel and Glofitamab as Second-Line Therapy for Relapsed or Refractory Patients With Large B Cell Lymphoma (NCT06213311) | M.D. Anderson Cancer Center | 2024-05-07 |
| A Study to Evaluate Adverse Events and Effectiveness of OnabotulinumtoxinA in Participants Undergoing Open Abdominal Ventral Hernia Repair for the Achievement of Primary Fascial Closure Without the Use of Component Separation Technique (NCT05606757) | AbbVie | 2024-05-07 |
| Ulixertinib in People With Histiocytic Neoplasms (NCT06411821) | Memorial Sloan Kettering Cancer Center | 2024-05-07 |
| Trial of Mirtazapine for Depression in IBD (NCT06309472) | King's College London | 2024-05-07 |